Skip to main content

CTXR

Stock
Health Care
Biotechnology

Performance overview

CTXR Price
Price Chart

Forward-looking statistics

Beta
0.70
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Company info

SectorHealth Care
IndustryBiotechnology
Employees19
Market cap$110.1M

Fundamentals

Enterprise value$20.2M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity1.47

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$5.76
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$8M
Avg trading volume (10 day)$5M
Put-call ratio

Macro factor sensitivity

Growth+3.6
Credit+5.3
Liquidity-3.4
Inflation+1.9
Commodities+3.5
Interest Rates-2.1

Valuation

Dividend yield0.00%
PEG Ratio11.63
Price to sales
P/E Ratio11.63
Enterprise Value to Revenue
Price to book0.32

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day
Ex. dividend day

News

After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)

The heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research (December 28, 2022)
Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial

Citius Pharmaceuticals Inc (NASDAQ: CTXR) reported topline results from the Phase 3 trial of I/ONTAK (E7777) for persistent or recurrent cutaneous T-cell lymphoma (CTCL).  I/ONTAK (E7777) is an engineered IL-2-diphtheria toxin fusion protein.

Benzinga (April 6, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free